Novel purification technologies for industrial biotherapeutic manufacture

Global demand for cheaper biotherapeutics, which represent many of the new tools in the fight against diseases such as cancer, drives the need for a reduction in manufacturing costs. A significant proportion of current costs arise from the purification technologies currently used to ensure the safety and efficacy of these treatments. Improvements to these technologies are fundamentally limited with the existing dominant technology reaching a point where it is unable to match performance increases in the rest of the manufacturing process. This will impact the ability for drug manufacturers to reach economies of scale and meet market demands from patients. Puridify’s novel nanofibre purification technology has the potential to revolutionise the industrial scale production of biotherapeutics. The material’s properties can overcome current manufacturing limitations by increasing productivity 10-fold, potentially reducing biotherapeutic manufacturing costs by up to 25%. This will play an important role in widening patient access to expensive drugs in both the UK and worldwide. Puridify seeks to develop key drivers for adoption under a CRD project.